Overview

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is an open, non comparative, multicentre phase II trial, to evaluate the efficacy and feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and by high-dose chemotherapy supported by ASCT.

Phase:

Phase 2

Details

Lead Sponsor:

International Extranodal Lymphoma Study Group (IELSG)

Treatments:

Carmustine
Cytarabine
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Methotrexate
Rituximab
Thiotepa